Engineering living cells to deliver nanoparticle therapies
Multiscale approaches to engineering living cells for nanotherapeutic delivery
['FUNDING_OTHER'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-11078352
This study is exploring new ways to use living cells to help deliver tiny drug-carrying particles right where they're needed in the body, making treatments more effective and reducing side effects for people with different health conditions.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11078352 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative methods to use living cells as delivery systems for nanoparticle therapeutics, which are tiny particles that can carry drugs to specific areas in the body. The project aims to overcome biological barriers that prevent effective delivery of these nanoparticles, ensuring they reach their intended targets while minimizing side effects. By understanding how living cells operate, the researchers hope to create strategies that enhance the precision and effectiveness of these therapies for various diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with conditions that could benefit from targeted drug delivery using nanoparticle therapeutics.
Not a fit: Patients who do not require nanoparticle therapies or have conditions that cannot be treated with this delivery method may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments with fewer side effects for patients requiring nanoparticle-based therapies.
How similar studies have performed: Other research has shown promise in using living cells for drug delivery, indicating that this approach could be a significant advancement in the field.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHAO, ZONGMIN — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: ZHAO, ZONGMIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.